Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Hadassah Medical Organization |
---|---|
Information provided by: | Hadassah Medical Organization |
ClinicalTrials.gov Identifier: | NCT00421369 |
In this project we aim to further refine indications for the use of the thyroid hormone - T3 for patients suffering from depression. We aim to identify a sub-group of patients who are more likely to respond to T3 and establish the time in the treatment course when T3 should be added. The results of this project could have significant, direct clinical implications.
Condition | Intervention |
---|---|
Major Depressive Disorder |
Drug: sertraline Drug: triiodothyronine (T3) Drug: reboxetine |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response. |
Estimated Enrollment: | 80 |
The lifetime risk for major depressive disorder (MDD) is 15% in the general population. Current treatment approaches emphasize the achievement of remission. Remission implies virtual absence of depressive symptoms and is associated with better function and a better overall prognosis than response, which is usually defined as a 50% reduction in symptom severity. Sixty percent or more of patients treated optimally with antidepressants remain un-remitted and will need additional treatment. A potentially effective but under-exploited strategy to augment antidepressant effects is concurrent administration of the thyroid hormone, triiodothyronine (T3). We previously demonstrated the clinical efficacy and safety of T3 administered concurrently with the SSRI, sertraline, in the context of a randomized, double-blind placebo-controlled trial. Although all the patients were euthyroid, remission rates were significantly higher in the sertraline plus T3 group and were associated with significantly lower baseline T3 values and a significant decrease in serum thyroid stimulating hormone (TSH) values during the course of treatment.
The study aims to:
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: Rena Cooper-Kazaz, MD | 00 972 2 6777184 | crena@hadassah.org.il |
Contact: Bernard Lerer, Prof. | 00 972 2 6777185 | lerer@cc.huji.ac.il |
Israel | |
Hadassah Medical Organization | |
Jerusalem, Israel |
Principal Investigator: | Rena Cooper-Kazaz, MD | Hadassah Medical Organization |
Study ID Numbers: | t3rbx-HMO-CTIL |
Study First Received: | January 11, 2007 |
Last Updated: | January 11, 2007 |
ClinicalTrials.gov Identifier: | NCT00421369 History of Changes |
Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Major depressive disorder Antidepressants Triiodothyronine (T3) |
Thyroid Function Augmentation Thyroid pathway genes |
Neurotransmitter Agents Depression Adrenergic Agents Psychotropic Drugs Depressive Disorder, Major Depressive Disorder Serotonin Uptake Inhibitors |
Serotonin Behavioral Symptoms Mental Disorders Mood Disorders Sertraline Antidepressive Agents Reboxetine |
Neurotransmitter Agents Neurotransmitter Uptake Inhibitors Depression Adrenergic Agents Molecular Mechanisms of Pharmacological Action Adrenergic Uptake Inhibitors Physiological Effects of Drugs Psychotropic Drugs Depressive Disorder, Major Depressive Disorder Serotonin Uptake Inhibitors |
Pharmacologic Actions Behavioral Symptoms Serotonin Agents Mental Disorders Therapeutic Uses Mood Disorders Sertraline Central Nervous System Agents Antidepressive Agents Reboxetine |